Stada Arzneimittel AG, a drugmaker focused on consumer health, is getting ready for a potential initial public offering (IPO) in the near future.
The company's private equity owners have selected Barclays Plc, Citigroup Inc., and HSBC Holdings Plc as bookrunners for the share sale, with Jefferies Financial Group Inc. and UBS Group AG also involved in the arrangement.
The IPO is expected to occur in Germany, with Stada potentially being valued at €10 billion ($11 billion) or more upon listing.
This move represents a significant milestone for the company as it aims to take advantage of market opportunities in the health sector.